111 related articles for article (PubMed ID: 36539000)
1. Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma.
Shi DM; Dong SS; Zhou HX; Song DQ; Wan JL; Wu WZ
Cell Signal; 2023 Apr; 104():110565. PubMed ID: 36539000
[TBL] [Abstract][Full Text] [Related]
2. Establishment of monoclonal HCC cell lines with organ site-specific tropisms.
Wan J; Wen D; Dong L; Tang J; Liu D; Liu Y; Tao Z; Gao D; Sun H; Cao Y; Fan J; Wu W
BMC Cancer; 2015 Oct; 15():678. PubMed ID: 26459277
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma.
Jin Y; Lee WY; Toh ST; Tennakoon C; Toh HC; Chow PK; Chung AY; Chong SS; Ooi LL; Sung WK; Lee CG
J Transl Med; 2019 Aug; 17(1):273. PubMed ID: 31429776
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
6. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome mutational landscape of metastasis in patient-derived hepatocellular carcinoma cells.
Zhou Q; Li Z; Song L; Mu D; Wang J; Tian L; Liao Y
Genes Dis; 2020 Sep; 7(3):380-391. PubMed ID: 32884992
[TBL] [Abstract][Full Text] [Related]
8. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
9. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.
Miao R; Luo H; Zhou H; Li G; Bu D; Yang X; Zhao X; Zhang H; Liu S; Zhong Y; Zou Z; Zhao Y; Yu K; He L; Sang X; Zhong S; Huang J; Wu Y; Miksad RA; Robson SC; Jiang C; Zhao Y; Zhao H
J Hepatol; 2014 Oct; 61(4):840-9. PubMed ID: 24859455
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNAs are differentially expressed in hepatocellular carcinoma cell lines with differing metastatic potential.
Fang TT; Sun XJ; Chen J; Zhao Y; Sun RX; Ren N; Liu BB
Asian Pac J Cancer Prev; 2014; 15(23):10513-24. PubMed ID: 25556502
[TBL] [Abstract][Full Text] [Related]
12. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.
Jiang H; Cao HJ; Ma N; Bao WD; Wang JJ; Chen TW; Zhang EB; Yuan YM; Ni QZ; Zhang FK; Ding XF; Zheng QW; Wang YK; Zhu M; Wang X; Feng J; Zhang XL; Cheng SQ; Ma DJ; Qiu L; Li JJ; Xie D
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4770-4780. PubMed ID: 32071245
[TBL] [Abstract][Full Text] [Related]
13. Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
Liu C; Zha Z; Zhou C; Chen Y; Xia W; Wang YN; Lee HH; Yin Y; Yan M; Chang CW; Chan LC; Qiu Y; Li H; Li CW; Hsu JM; Hsu JL; Wang SC; Ren N; Hung MC
J Hepatol; 2021 Apr; 74(4):907-918. PubMed ID: 33031845
[TBL] [Abstract][Full Text] [Related]
14. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4.
Jiang X; Wang G; Liu Y; Mei C; Yao Y; Wu X; Chen X; Ma W; Li K; Zhang Z; Yuan Y
Cancer Lett; 2021 Feb; 499():109-121. PubMed ID: 33259899
[TBL] [Abstract][Full Text] [Related]
15. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic Analysis to Identify a Multi-mRNA Signature for the Prediction of Metastasis in Hepatocellular Carcinoma.
Liu L; Wang B; Han Q; Zhen C; Li J; Qu X; Wang F; Kong X; Zheng L
DNA Cell Biol; 2020 Nov; 39(11):2028-2039. PubMed ID: 33147069
[TBL] [Abstract][Full Text] [Related]
17. Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression.
Ramesh V; Ganesan K
Int J Cancer; 2016 Oct; 139(7):1586-97. PubMed ID: 27194100
[TBL] [Abstract][Full Text] [Related]
18. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma.
Yang B; Feng X; Liu H; Tong R; Wu J; Li C; Yu H; Chen Y; Cheng Q; Chen J; Cai X; Wu W; Lu Y; Hu J; Liang K; Lv Z; Wu J; Zheng S
Oncogene; 2020 Oct; 39(42):6529-6543. PubMed ID: 32917956
[TBL] [Abstract][Full Text] [Related]
19. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
20. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
